NCT06974565View on ClinicalTrials.gov

A Study to Investigate the Pharmacokinetics of AZD2389 in Healthy Participants When Administered Alone and in Combination With Quinidine

PHASE1CompletedINTERVENTIONAL
Enrollment

16

Participants

Timeline

Start Date

May 12, 2025

Primary Completion Date

July 18, 2025

Study Completion Date

July 18, 2025

Conditions
Advanced Chronic Liver DiseaseHealthy Participants
Interventions
DRUG

AZD2389

AZD2389 will be administered orally.

DRUG

Quinidine

Quinidine will be administered orally.

Trial Locations (1)

21225

Research Site, Brooklyn

Sponsors

Lead Sponsor

AstraZeneca

Collaborators (1)

Parexel
All Listed Sponsors
collaborator

Parexel

INDUSTRY

lead

AstraZeneca

INDUSTRY